Moderna Drops 7% Despite a Fresh Wolfe Research Upgrade, BioNTech Slips

Moderna shed 7% of Tuesday's 14% Wolfe Research upgrade rally, while BioNTech's 2% dip confirms the selloff is Moderna-specific.

IBB barely moved while Moderna's $59 billion cap prices in Merck's unapproved intismeran program against just $145 million in quarterly revenue.

Moderna stock is giving back a large chunk of Tuesday's rally. The pullback reopens a question that a summer melt-up has largely papered over: what does a market capitalization near $59 billion actually value on this income statement?

Moderna ( NASDAQ:MRNA ) stock is down 7% to $148.02 midday Wednesday, and no fresh company news is on the wire to explain the slide. Also lower, BioNTech SE ( NASDAQ:BNTX ) stock is down 2% to $111.60, a much shallower giveback that suggests the pain is Moderna-specific.

The iShares Biotechnology ETF ( NASDAQ:IBB ) is down 0.6% to $215.04, so the biotech cluster is barely wobbling. Meanwhile, the SPDR S&P 500 ETF Trust ( NYSEARCA:SPY ) is unchanged at $765.57, keeping the broad market backdrop quiet.

Moderna stock closed 14% higher on Tuesday, back above $150, after Wolfe Research upgraded Moderna stock to Peer Perform from Underperform. The firm offered no new price target and pegged unadjusted peak sales at $9.2 billion across the four main indications for intismeran, the personalized cancer vaccine Moderna is developing with Merck ( NYSE:MRK ).

That upgrade capped a violent ascent. Moderna stock was up 439% year to date through Tuesday's close, so a 7% giveback here reads as profit-taking after a rally that stretched the chart well beyond any near-term news catalyst.

The move has been remarkably compressed on a shorter frame as well. Moderna stock was up 194% over the trailing month through Tuesday's close, so a 7% single-day pullback sits well within the range of recent daily swings for the name.

What Happens After A $1,000,000 Retirement?

How do you continue to grow a seven-figure portfolio in retirement? The last thing you want is to run out of money, you want your money to generate lasting income while you enjoy your life.

Learn seven strategies high net worth investors use with new report: The Seven Secrets of High Net Worth Investors from Fisher Investments. Get your guide here (sponsor)

Modest Fundamentals for a $59 Billion Cap

Moderna carries no trailing P/E ratio, because there is no trailing profit to divide into. Q2 2026 revenue was $145 million, up 2.1% year over year, and the loss of $1.97 per share matched the $1.97 consensus estimate exactly. The net loss narrowed to $782 million from $825 million a year earlier, aided by cost of sales that fell 22% to $93 million on manufacturing productivity gains.